Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118343) titled 'A Multicenter, Dual-Cohort Exploratory Clinical Study of Anlotinib Plus Bemelstobart as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma' on Feb. 4.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: The First Affiliated Hospital of Zhengzhou University
Condition:
Esophageal squamous cell carcinoma
Intervention:
Experimental group:Anlotinib: starting dose 12 mg orally once daily (taken before breakfast on an empty stomach
dosing should occur at approximately the same time each day). Administer for 2 consecutive weeks followed by 1 week off
every 21 day...